Molecular characterization of the detergent-insoluble cholesterol-rich membrane microdomain (raft) of the central nervous system  by Maekawa, Shohei et al.
Review
Molecular characterization of the detergent-insoluble cholesterol-rich
membrane microdomain (raft) of the central nervous system
Shohei Maekawa a,*, Satoshi Iino b, Seiji Miyata c
aDepartment of Life Science, Graduate School of Science and Technology, Kobe University, Rokkodai 1-1, Kobe 657-8501, Japan
bDepartment of Physiology and Cell Biology, University of Nevada School of Medicine, Reno, NV 89557-0046, USA
cDepartment of Applied Biology, Kyoto Institute of Technology, Kyoto 606-8585, Japan
Received 9 April 2002; received in revised form 20 August 2002; accepted 20 August 2002
Abstract
Many fundamental neurological issues such as neuronal polarity, the formation and remodeling of synapses, synaptic transmission, and
the pathogenesis of the neuronal cell death are closely related to the membrane dynamics. The elucidation of functional roles of a detergent-
insoluble cholesterol-rich domain (raft) could therefore provide good clues to the molecular understanding of these important phenomena, for
the participation of the raft in the fundamental cell functions, such as signal transduction and selective transport of lipids and proteins, has
been elucidated in nonneural cells. Interestingly, the brain is rich in raft and the brain-derived raft differs in its lipid and protein components
from other tissue-derived rafts. Since many excellent reviews are written on the membrane lipid dynamics of this microdomain, signal
transduction, and neuronal glycolipids, we review on the characterization of the raft proteins recovered in the detergent-insoluble low-density
fraction from rat brain. Special focus is addressed on the biochemical characterization of a neuronal enriched protein, NAP-22, for the lipid
organizing activity of this protein has become increasingly clear.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Raft: structure and function
The clustering of cholesterol and (glyco)sphingolipids
within the cell membrane causes the formation of distinct
domains or lipid rafts [1–4]. GPI-anchored proteins and
acylated proteins associate with the outer and the inner
leaflet, respectively [5]. Owing to the highly saturated long-
chain fatty acid and sphingolipid base moiety, sphingolipids
in purified form would be in the gel phase at physiological
temperatures. However, cholesterol preferentially associates
with these sphingolipid domains and promotes conversion
to a liquid ordered state [6]. The saturated acyl chains
characteristic of GPI-anchored proteins associate with this
liquid ordered state [5,7–11].
In contrast to the fairly well-characterized outer leaflet
lipids, little information is available concerning the cytoplas-
mic leaflet lipids [4,12,13]. Since many acylated proteins
localize on the inner leaflet of the raft, the elucidation of the
raft structure in this sphingolipid-poor leaflet is of great
importance [14–18]. Also important is the molecular char-
acterization of the communication between outer and inner
leaflet. The co-redistribution of the doubly acylated Src
family protein kinases, after the cross-linking of cell surface
GPI-anchored proteins or gangliosides using antibodies or
toxins, suggests the presence of such communication [19,20].
The elucidation of such communication will be essential to
understand the molecular roles of raft in signal transduction.
Another important role of the raft is the transport and
retention of lipids and proteins within the cell. Site specific
sorting of membrane components is essential to establish
and maintain the cell polarity observed in epithelial cells and
neurons [21,22]. It is from the studies on the specific sorting
of membrane domains in epithelial cells that the concept of
‘‘raft’’ was embodied [23–25]. It is well recognized that
cellular cholesterol levels are precisely controlled through
biosynthesis, influx into and efflux from cells via lipopro-
teins. Since cholesterol is one of the major lipids in the raft,
much attention has been paid to the roles of the raft in the
intracellular trafficking and compartmentation of cholesterol
[26–30].
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2. Brain, a cholesterol- and sphingolipid-enriched tissue
The largest pool and concentration of cholesterol in the
body exists in the brain [31–34]. Being a constituent of cell
membrane, cholesterol is important for the function of this
organ, and inborn defects in cholesterol metabolism and
transport are associated with serious neurological and men-
tal dysfunctions [35–44]. Alterations in cholesterol metab-
olism occur with age [45–47] and have been implicated in
the pathogenesis of Alzheimer’s disease, because the pro-
duction of Ah is regulated by membrane cholesterol and the
accumulation of the peptide occurs on the ganglioside GM1
located on raft [48,49]. Studies on cholesterol metabolism
discovered the functional roles of apolipoprotein E, and the
elucidation of the allele type of apolipoprotein E as a risk
factor for the Alzheimer’s disease further illuminated its
receptors as signaling molecules [50,51]. In addition, recent
studies showed the importance of cholesterol-derived neuro-
steroids, cholesterol modification of proteins, and supply of
cholesterol in early development, synaptogenesis, and syn-
aptic functions [52–60].
There exist some pioneering works focused on the lipid
composition, asymmetrical distribution, and its changes in
the synaptic plasma membrane during brain development
[27,61–64]. Interestingly, an asymmetrical distribution of
cholesterol in the synaptic membrane (f 85% in the inner
leaflet) reduces after chronic ethanol treatment or aging
[27]. Furthermore, knockout mice deficient in the low-
density lipoprotein receptor, apolipoprotein E, or both
proteins, also showed the increase of cholesterol in the outer
leaflet [64].
Brain is also a rich source of gangliosides and the content
and chemical characteristics of brain gangliosides are under
genetic control, differing in various brain regions and during
development. Much attention has been paid on the various
functions of the gangliosides in various neuronal events,
including differentiation and survival, signal transduction,
synaptic transmission, and neuronal plasticity [65–71]. The
study focused on the functional roles of cholesterol, and
sphingolipid-enriched domain (raft) is therefore of central
importance for the molecular understanding of the central
nervous system.
3. Identification of a NAP-22 localized fraction as the
brain-derived raft
The growth cone is a neuronal specialized sensory and
motor apparatus localized at the tip of the neuronal process
[72,73]. During the characterization of membrane compo-
nents of the growth cone, we noticed a very acidic calm-
odulin-binding protein present in a Triton-insoluble
membrane fraction. Since molecular cloning showed that
the molecular mass of this protein is 22 kDa, the protein was
termed NAP-22 (neuronal acidic protein of 22-kDa) [74].
Further studies showed the effect of calmodulin on the
phosphorylation of NAP-22 with protein kinase C [75,76].
Although the homology between NAP-22 and CAP-23
(cortical cytoskeleton-associated protein) was not so evident
at this time, these proteins were found identical after the
recloning of CAP-23 [77,78]. The same protein is also
called BASP1 [79]. From the studies using knockout and
knockin mice, Frey et al. [80] showed the participation of
CAP-23/NAP-22 on the membrane dynamics through the
regulation of the actin dynamics. In contrast, the biochem-
ical analysis was not enough to explain its cellular function.
The protein was assumed to be a hydrophilic protein
because this protein had no hydrophobic sequence. Bio-
chemical fractionation studies of the brain tissue showed
that the protein was present in the Triton-soluble and Triton-
insoluble membrane fraction, not in the soluble fraction.
Further characterization showed the N-terminal myristoyla-
tion of this protein [81]. Myristoylation, however, explains
only the membrane association. The molecular mechanism
of the Triton-insolubility was still to be elucidated. Interest-
ingly, the Triton solubility of NAP-22 decreased gradually
during the maturation of the brain. Since the localization of
NAP-22 in the synaptic membranes, such as presynaptic
membrane and synaptic vesicles, was very interesting
[82,83], the fractionation of the Triton-insoluble structure
was then attempted.
After a sucrose density gradient centrifugation, the NAP-
22-enriched Triton-insoluble membrane domain was recov-
ered in a low-density region (f 0.6 M sucrose) as a white
Fig. 1. SDS-PAGE patterns of the Triton-insoluble low-density fraction
(raft) of rat brain. (A) Fractions isolated from P5, P21, and P50 forebrains
were analyzed using a 10% acrylamide gel. (B) Rafts from the forebrain of
2-week-old rat (P14) (B) and from cultured cortex neurons (N, 8 days in
culture) were compared using an 11% gel. (C) The raft fractions from
myelin fraction (My), growth cone fraction (GC), and forebrain (B) were
electrophoresed in a 12.5% gel. M, marker proteins (68, 43, 29, and 21 k,
from top to bottom).
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layer separated clearly from other more high-density frac-
tions. Partial amino acid sequencing of some major proteins
in this fraction showed the localization of GAP-43 and the
trimeric G-protein Go in addition to NAP-22 [84]. Further
2D PAGE and Western blot analysis showed the enrichment
of other G-proteins (Gs, Gi), Src family protein kinases (Src,
Fyn, Lyn), and some GPI-anchored proteins [84]. Since
Triton-insolubility, low-density, and the enrichment of GPI-
anchored proteins and doubly acylated proteins were the
characteristics of the raft, the NAP-22 enriched fraction was
hence judged to be the brain-derived raft [25,85]. Fig. 1A
shows the SDS-PAGE pattern of the raft components
derived from three different developmental stage brains. A
couple of major proteins exist in all three preparations.
Since these proteins are also present in the raft fractions
obtained from cultured primary neurons and the growth
cone fraction but not myelin fraction (Fig. 1B and C), the
relative amount of the myelin proteins in the raft fraction is
fairly low. As described above, these major proteins were
identified as NAP-22, GAP-43, a and h subunit of trimeric
G-protein Go, and tubulin. Among these proteins, NAP-22
localized predominantly in the raft [84,86].
4. Isolation of the brain-derived raft
The raft domain is recovered in a low-density fraction
after the treatment of the membrane with the nonionic
detergent such as Triton X-100 and sucrose density gradient
centrifugation [14,23,24]. The enrichment of cholesterol and
sphingolipids is ascribed to be responsible for the detergent
insolubility. As little expression of caveolin is observed in
brain tissue, the caveola domain is hard to detect in the
fraction obtained [14,15,17,87]. Since the detergent extrac-
tion leads to raft aggregation, it is difficult to separate
individual rafts. Alternatively, nondetergent methods were
applied to avoid detergent-induced membrane mixing. One
of such methods employed sonication and the other used an
alkaline treatment to disrupt membranes before the density
gradient centrifugation [88–90]. The low-density fractions
prepared from these methods were also considered to be the
raft. The sonication method, however, was judged not to be
applicable to the brain because the brain tissue contains
much amount of low-density membrane fractions such as
the myelin membrane and synaptic vesicles. Fig. 2 shows
the SDS-PAGE patterns of the low-density fractions pre-
pared from the synaptic plasma membrane using these three
methods. A comparison of the protein components of these
fractions clearly shows that these fractions are not identical.
Here we focus on the protein components recovered in the
detergent-insoluble raft because this method is able to
handle a fairly large amount and also easy to reproduce.
Very little protein recovery (f 0.1% of total protein) in the
raft fraction has been reported using nonneural cells and
tissues [13,14,88]. In contrast, a fairy large amount of
protein was recovered from the brain (more than 1%) even
after repeated washes using Triton X-100. The brain is
hence a raft-enriched tissue.
5. Extracellular proteins
The localization of GPI-anchored proteins to the raft is
well recognized. Prion protein, probably the most famous
GPI-anchored protein, also localizes in the raft [91,92].
Lipid modulations were shown to effect the formation of
the Scrapie type prion protein [93]. Recent studies showed
that prion is a synapse-localized protein associated with the
dystrophin complex [94,95]. These results could provide a
good clue to elucidate the neuronal function of the protein.
Concerning the GPI-anchored cell adhesion molecules,
Olive et al. [96] showed the localization of F3 in the raft
and its interaction with L1 in cerebellum. F3 is also known
to interact with paranodin (casper) in the course of myeli-
nated axon formation [97]. Thy-1 is a small GPI-anchored
protein abundant in brain and is known to participate in
axonal outgrowth, synaptic regulation, and synaptic trans-
mission [98–100]. A search for activity-regulated genes
resulted in the identification of a small GPI-anchored
protein, CPG-15 (activity-regulated candidate plasticity
gene). CPG-15 promotes dendritic growth and axon arbor
elaboration in an activity-dependent manner [101,102].
In order to identify the GPI-anchored proteins in the raft
from 2-week-old rat brain, amino acid sequences of the
major proteins were analyzed after the solubilization with
PI-PLC treatment and deglycosylation. The presence of N-
CAM-120, F3, T-cadherin, and Thy-1 was identified with
this analysis and/or Western blot [103]. T-cadherin is a
truncated form of cadherin, and a recent study suggested
Fig. 2. SDS-PAGE analysis of the low-density fractions obtained from the
synaptic plasma membrane fraction from 6-week-old rat forebrain treated
with Triton X-100 [1], pH 11 buffer [2], and sonication [3] before a density
gradient centrifugation. M, marker proteins (97, 68, 43, and 29 k, from top
to bottom).
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that LDL is a physiologically relevant ligand for T-cadherin
[104,105]. In addition to these proteins, a novel protein
(Kilon), which belongs to a subfamily (IgLON family) of
the immunoglobulin superfamily, was detected as one of the
GPI-anchored protein [103]. Further immunohistochemical
studies using specific antibodies to Kilon or OBCAM,
another IgLON family protein, showed the localization of
these proteins in the post synaptic density region [106]. The
region-specific expression of these proteins in developmen-
tally regulated manners suggests their important roles in the
formation and maintenance of the CNS [107–111]. Differ-
ent localization of various GPI-anchored proteins on the
neuronal surface was also shown by Madore et al. [112].
Following this work, segregation of gangliosides GM1 and
GD3 on the cell membrane is reported [113]. These results
clearly show that there exist a variety of raft in the protein
and lipid components.
Since GPI-anchored proteins have no transmembrane
domains, the elucidation of the mechanism by which these
proteins transmit the extracellular signal is important to
understand the signaling pathways of cells. For example,
GPI-anchored protein TAG-1 and ganglioside GD3 caused
the activation of cellular tyrosine kinases through an
unknown pathway [114]. In case of the glia-derived neuro-
trophic factor (GDNF) family ligand, the signal is trans-
mitted through the recruitment of the signaling complex
(ligand/GPI-anchored receptor/transmembrane protein,
RET) to raft [115–119]. Future studies focused on the
molecular interaction of GPI-anchored proteins are clearly
needed to elucidate the background of the cell-to-cell
interactions in the nervous system.
6. Transmembrane proteins
Curiously, there is no transmembrane protein as a major
component in the brain-derived raft (Fig. 1). The identifi-
cation through the Western blot analysis has hence been the
major method to detect these proteins. One of the raft
marker proteins, flotillin, originally found in the caveola
of 3T3-L1 mouse fibroblast differentiated to adipocyte, was
shown to be in the neuronal raft [120,121]. Since the
localization of some ion channels in raft and the regulation
of their function with lipids are just beginning to notice,
further studies will be very promising to elucidate the
functional role of raft in the neuronal signal transmission
[122,123]. Another transmembrane raft protein was identi-
fied through the studies on the regulation of Src kinase
family proteins in brain. This protein, called Cbp, regulates
the Src-family protein kinases that are also localized in
neuronal raft [124].
Although the enrichment of some receptor-type tyrosine
kinases, the insulin receptor and TrkB (brain-derived neuro-
trophic factor receptor), in the brain-derived low-density
fraction prepared by the sonication method was reported,
further study showed the solubilization of these proteins
with Triton X-100 [125,126]. Ah is a 40–43-amino-acid
peptide derived by the proteolytic cleavage of the integral
membrane amyloid precursor protein (APP) [127]. Partial
localization of APP in raft, Ah binding to ganglioside GM1,
and the modulatory effect of cholesterol on the specific
cleavage of APP indicated the importance of raft in the
pathogenesis of Alzheimer’s disease [48,49,128–136].
7. Proteins associated to the inner leaflet of raft
7.1. Molecular characterization of NAP-22
NAP-22 has properties very similar to GAP-43 (growth
associated protein of 43 kDa, also called neuromodulin) and
MARCKS (myristoylated alanine-rich C-kinase substrate)
[137,138]. They are relatively small acidic proteins with
abnormal behavior in SDS-PAGE and bind calmodulin,
although the amino acid sequences of the calmodulin bind-
ing sites are different from each other. These proteins are
resistant to boiling treatment or acid precipitation. Mem-
brane association is due to the myristoylation (MARCKS
and NAP-22) or palmitoylation (GAP-43), and the phos-
phorylation by protein kinase C inhibits the calmodulin
binding [137–145].
Considering the low dissociation constant between NAP-
22 and calmodulin (1.2 nM), the high cellular content of
these proteins (60 AM calmodulin, 20f 40 AM NAP-22),
and the localization of NAP-22 in synaptic regions, calm-
odulin could participate in the neuronal membrane dynam-
ics through the interaction with NAP-22 at the synaptic
region [74,137,138]. Since alcohol extraction was effective
to solubilize NAP-22 and GAP-43, these proteins were
assumed to bind to the membrane through interactions with
membrane lipids. The lipid components of brain raft were
then studied.
7.2. Lipid components of raft and cholesterol-dependent
lipid binding of NAP-22
An analysis of lipid components recovered in the Triton-
raft from the 2-week-old rat brain showed the enrichment of
cholesterol and sphingomyelin (SM) as observed in other
rafts, although the enrichment of SM was not so evident
compared to the case of cultured cells. Interestingly, the
recovery of phosphatidylcholine (PC) and phosphatidyle-
thanolamine (PE) in the raft was clearly observed [85].
Since the enrichment of PC, PE, and cholesterol was also
reported in the GPI-anchored protein-rich fraction (which
corresponds to the raft) of chicken brain prepared with
Nonidet P-40, there may be some factor(s) which assemble
these lipids in the brain-derived raft [146].
An attempt to extract cholesterol using methyl-h-cyclo-
dextrin (MCD) showed a dose-dependent and specific
solubilization of NAP-22 (Fig. 3). It is calculated that the
extraction of 460 cholesterol molecules causes the solubili-
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zation of one NAP-22 molecule. Since PC was the main
glycerolipid in the raft, the effect of cholesterol on the
liposome binding of NAP-22 was studied using PC/choles-
terol liposomes. Increasing amounts of NAP-22 to a con-
stant amount of PC/cholesterol liposome proved a dose-
dependent binding, and a Scatchard plot analysis showed a
binding ratio of about 760 cholesterol molecules/1 molecule
of NAP-22. Assuming an even distribution of cholesterol in
the inner and outer leaflet of the liposome, this means one
NAP-22 molecule covers a region composed of 380 choles-
terol molecules in the liposome. This figure corresponds
well with that obtained in the extraction experiment [85].
Interestingly, changing the headgroup from zwitterionic
phosphatidylcholine to anionic phosphatidylserine virtually
eliminated the binding of NAP-22 to liposomes even in the
presence of cholesterol. This result was further confirmed
by Epand et al. using multilamellar vesicles composed of 1-
stearoyl-2-phosphatidylcholine, dioleoylphosphatidylcho-
line, and dipalmitoylphosphatidylcholine. They also showed
that NAP-22 promotes the formation of cholesterol micro-
domain in liposomes composed of cholesterol and PC [147].
The lipid-organizing ability of NAP-22 to induce cholesterol
microdomain in the membrane is thus different from other
cholesterol binding proteins such as caveolin and START
(StAR-related lipid transfer) domains [148,149].
Since NAP-22 shows a Ca2 + -dependent calmodulin
binding, the effect of calmodulin on this binding was
interesting. Calmodulin not only inhibited the binding but
also caused the dissociation of NAP-22 from the liposomes.
Further studies showed that NAP-22 also binds PC/PE
liposome to some extent. Since PE has much higher Tm
than PC because of its small headgroup, this result suggests
the importance of PE in the raft formation in the inner
leaflet. The three major lipid species in the brain-derived raft
were therefore shown to interact with NAP-22.
In order to elucidate the molecular background of neuro-
degeneration, the mechanism of LDL, LDL receptor-related
proteins (LRPs), apolipoprotein E, and Ah in the mainte-
nance of the transbilayer distribution of cholesterol and their
effects on the signaling mechanism are under intense
investigation [150–158]. Considering the asymmetric dis-
tribution of cholesterol in the synaptic plasma membrane,
further studies on the role of NAP-22 on the distribution and
organization of cholesterol within the neuronal membrane
will be important to understand the lipid–protein interac-
tions in signal transduction.
7.3. Localization and cellular function of NAP-22 in brain
and neurons
Since NAP-22 shows a specific localization to the raft,
NAP-22 provides a good marker to identify raft domains in
neurons and in brain sections. The Western blot analysis
showed a predominant expression of NAP-22 in brain but
not in other tissues [74]. NAP-22 immunoreactivity was
detected through the whole brain, and dense staining was
observed in the forebrain including cerebral cortex, hippo-
campal formation, olfactory bulbs, basal ganglia, and tha-
lamus. Immunoreactivity was distributed densely at the
neurophil, whereas nerve cells and nerve fibers had little
or no reaction. NAP-22 immunoreactivity was observed to
be associated mainly with pre- and postsynaptic membranes
and synaptic vesicles [82]. Investigation on the changes in
the localization of NAP-22 during the development of the
neuronal polarity in vitro and in vivo, using cultured hippo-
campal neurons and developing cerebellum neurons,
showed a gradual localization of the protein to the synaptic
region [159]. The time course of the accumulation was
much slower than that of GAP-43 in hippocampal neurons.
Fig. 3. Stoichiometric solubilization of cholesterol and NAP-22 with MCD.
(A) After incubation on ice for 60 min with MCD (1, 0 mM; 2, 5 mM; 3, 10
mM; 4, 15 mM; 5, 30 mM; 6, 50 mM), the samples were centrifuged at
100,000 g for 30 min to separate supernatant (sup) and pellet (ppt).
Pellets were suspended in the original volume to represent the solubilizing
effect after the analysis of the same volume in SDS-PAGE. (B)
Solubilization of NAP-22 and cholesterol with MCD. The amounts of
NAP-22 and cholesterol in the supernatants were plotted for used MCD
concentrations.
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In the cerebellar sections, the synaptic accumulation of
NAP-22 was not evident in 1-week-old neurons, although
the accumulation of VAMP-2, a synaptic vesicle protein,
was already observed at this stage. These results suggest that
NAP-22 plays an important role in the maturation and/or the
maintenance of synapses by controlling cholesterol-depend-
ent membrane dynamics.
Synergistic participation of GAP-43 and CAP-23 (NAP-
22) on the neurite plasticity is observed in adult double
transgenic mice [80,160]. Expression experiments of these
proteins in COS7 and PC12B cells showed that GAP-43,
CAP-23, and MARCKS modulate PI(4,5)P2 at the plasma
membrane raft and regulate cell cortex actin dynamics
[161]. Strong binding of NAP-22 to liposomes containing
PIP or PIP2 is also observed [162]. These results suggest
that NAP-22 organizes specific lipid species such as choles-
terol, PE, PIP, and PIP2 at the raft domain.
8. Calcium-dependent raft-localizing proteins
Calcium ions play multiple functions in the nervous
system. One possible participation of Ca2+ ions is to
reconstruct the raft through the interaction of calmodulin
with NAP-22 as described above. To investigate the other
possible participation, calcium-dependent raft binding pro-
teins were screened. After the incubation of an EGTA-
extracted cytosolic fraction with the raft in the presence of
Ca2+ ions, the raft fraction was recovered and washed
several times with a solution containing Ca2+ ions. Ca2+-
dependent binding proteins were then eluted with a solution
containing EGTA. SDS-PAGE analysis revealed the specific
association of several proteins. Amino acid sequencing and
Western blot identified these proteins as annexin VI, protein
kinase C a, and neurocalcin a. Although the Ca2+-depend-
ent membrane association of these proteins has been well
known, this study identified their binding domain as the raft
microdomain within the membrane [163]. Since little is
known on the targets of these proteins, further investigation
will provide much more information on the Ca2+-dependent
signaling mechanism. In addition, considering the specific
lipid composition of the raft described above and the
selective association of these proteins, identification of the
membrane-binding region within these proteins will provide
good probes to the membrane microdomains.
9. Localization of cytoskeletal proteins and their
regulators
As described above, there exist three different membrane
fractionation methods before the density gradient centrifu-
gation to separate raft domains. The localization of Rho
family proteins in the raft fraction was reported using the
sonication method in fibroblastic cells [164]. To examine
the heterogeneity of the components in these raft fractions,
localization of these proteins in the sonication-raft and the
Triton-raft obtained from the sonication-raft was compared
using the synaptic plasma membrane fraction. Although the
enrichment of Rac1, RhoA, and Cdc42 in the sonication-raft
was confirmed, further extraction with Triton showed the
localization of Rac1, but not RhoA nor Cdc42, in the Triton-
raft. Interestingly, some part of Rac1 in the Triton-raft was
solubilized after incubation with MCD. The localization
pattern of Rac1 in neurons observed with an immunocyto-
chemical technique, however, was quite different from that
of NAP-22 [165]. This result further supports the idea that
there exist various rafts even in one neuron [112,113].
The localization of Rac1, gelsolin, and an actin regula-
tory phospholipid (PIP2) in the raft further suggests the
participation of raft in the neuronal morphological change
[80,160,161,165,166]. A recent finding that raft is the
localizing place of a new type of phosphatidylinositol 4-
kinase (PI4KII) indicates that raft is not only the storehouse
of the signaling lipid molecules but also the factory of these
important molecules [167,168]. Interestingly, tubulin, the
microtubule building block, was also present as the major
protein in the brain-derived raft [84]. The participation of
lipid modification of tubulin on the localization was shown
by Palestini et al. [169]. The localization is also ascribed to
the presence of a palmitoylated neuronal tubulin binding
protein, SCG10, in the raft [170]. Since the localization of
tubulin was not so evident in the rafts from other tissues or
cells, the elucidation of the localization mechanism and the
role of tubulin in the raft could be a good clue to understand
the function of neuronal raft.
10. Rafts and membrane cycling
Since the localization of NAP-22 on the synaptic vesicle
(SV) was shown by an immunohistochemical study, the
purification of the SV was performed to evaluate the amount
of NAP-22 on SV. NAP-22 and synaptophysin, an SV
marker, showed a resembled pattern during SV purification.
An immunoprecipitation of this SV fraction with anti-
synaptotagmin antibody showed the precipitation of synap-
tophysin and NAP-22 together with synaptotagmin. N-
CAM, a synaptic plasma membrane protein, however, was
not precipitated. These results further confirmed the pres-
ence of NAP-22 and hence the presence of the raft in SV. A
densitometric analysis showed that NAP-22 comprised
1.3% of the total protein in SV; this means about 1.8
molecules of NAP-22 in one SV. Since two molecules of
synapsin I are estimated to be in one SV, the molar amount
of NAP-22 is comparable to that of synapsin I, a well-
known synaptic vesicle protein [171]. The localization of
vesicular H + -ATPase in the rafts of the chromaffin granule
membrane and SV and the finding that some SNARE
proteins and synaptophysin have affinity to cholesterol
suggest the participation of the raft in the neuronal mem-
brane cycling [172–176].
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11. Other raft proteins
In addition to the major protein components listed above,
a variety of important proteins exist in the neuronal raft. For
example, the raft-localization of some of the postsynaptic
density proteins was shown recently [177,178]. At present,
the identification of the raft-localized transmembrane pro-
teins in neurons is poor compared to the outer leaflet- and
inner leaflet-localized proteins. Some GPI-anchored pro-
teins are known to recruit transmembrane proteins to the
raft after the binding of their ligands [119,179]. The exclu-
sion of raft proteins during the signal transduction is also
known [180]. Further studies on the lipid-binding domains
in the raft-localized transmembrane proteins will be useful
to identify the raft-localized proteins from the protein data-
base in silico. Introduction of novel lipid probes will also
contribute to the further characterization of the lipid–protein
interactions in various rafts [181–183].
12. Summary and perspectives
The characterization of growth cone membrane proteins
resulted in the identification of an acidic protein, NAP-22, as
a major neuronal raft component. Trimeric G-protein Go,
GAP-43 (neuromodulin), tubulin, several GPI-anchored
proteins, and various signal transducing proteins were also
detected in the raft from CNS. The enrichment of cholesterol,
PC, and PE was detected compared with the lipid compo-
nents of raft fractions from cultured cells or other tissues.
Further characterization of NAP-22 showed that this protein
interacts with cholesterol within the membrane and induces a
cholesterol-rich domain in the membrane. The enrichment of
these lipids in the brain-derived raft is, hence, partly ascrib-
able to the localization of NAP-22. Considering the high
expression, cholesterol assembly, calmodulin binding, and
C-kinase phosphorylation, NAP-22 seems to have a pivotal
role in the regulation of the membrane dynamics in neurons.
Through the characterization and localization studies of the
brain-derived raft components, the variety of the raft not only
in protein composition but also in lipid composition has
become increasingly clear. In addition, there occur mixing
and segregation of the raft components during the neuronal
function. Since many neuronal functions such as secretion of
neurotransmitters, internalization of various receptors, for-
mation and remodeling of synapses are based on the mem-
brane dynamics, the elucidation of the roles of the raft in
these events is of great importance to understand the molec-
ular mechanism of the central nervous system.
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